![[current-page:title] logo](/sites/default/files/styles/logo/public/default_images/_no-logo.png?itok=8OH0tuUw){kind=logo}
Corporate information
Registration country
Company type
Singapore-based cancer therapeutics company which, focuses on the discovery, research, and clinical development of small molecule drugs.Funding rounds
Venture USD 5,000,000
USD 5,000,000 ( )
| Investor | Profile | Country | |
|---|---|---|---|
|
Mitsui & Co Global Investment Inc (三井グループ) |
Other USD 112,500,000
USD 112,500,000 ( )
Global exclusive license to develop and commercialize multi-kinase inhibitor SB1317.
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Tragara Pharmaceuticals Inc | Development of proprietary drugs for the treatment of cancer and inflammation-related disorders. | USD 112,500,000 (USD 112,500,000) |
Series B USD 26,000,000
USD 26,000,000 ( )
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Aravis Venture Associates AG (Aravis Ventures) | Led the round. (Co-led the investment round.) | ||
|
Bio*One Capital Pte Ltd | (USD 60,000,000) (Co-led the investment round. Repeat investment.) | ||
|
|
Lacuna LLC | |||
|
ZKB Start-up Finance | (Repeat investment.) |
Investment activity status
Not investing